UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13D
(Rule 13d-101)
Information to be Included in Statements Filed Pursuant
to § 240.13d-1(a) and Amendments Thereto Filed
Pursuant to § 240.13d-2(a)
Under the Securities Exchange Act of 1934
(Amendment No. 1)
GNC Holdings, Inc.
(Name of Issuer)
Class A Common Stock, $0.001
par value per share
(Title of Class of Securities)
36191G107
(CUSIP Number)
Harbin Pharmaceutical Group Co., Ltd
No. 68, Limin West Fourth Street
Limin Development Zone
Harbin, People’s Republic of China
(86) 0451-51961111
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
November 4, 2019
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (“Act”), or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
1 | Names of Reporting Persons
Harbin Pharmaceutical Group Co., Ltd | |||||
2 | Check the Appropriate Box if a Member of a Group (a) ☐ (b) ☐
| |||||
3 | SEC Use Only
| |||||
4 | Source of Funds
WC | |||||
5 | Check if Disclosure of Legal Proceedings is Required Pursuant to Item 2(d) or 2(e) ☐
| |||||
6 | Citizenship or Place of Organization
People’s Republic of China | |||||
Number of Shares Beneficially Owned by Each Reporting Person With
| 7 | Sole Voting Power
58,813,084 shares of Common Stock | ||||
8 | Shared Voting Power
0 shares of Common Stock | |||||
9 | Sole Dispositive Power
58,813,084 shares of Common Stock | |||||
10 | Shared Dispositive Power
0 shares of Common Stock | |||||
11 | Aggregate Amount Beneficially Owned by Each Reporting Person
58,813,084 shares of Common Stock | |||||
12 | Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐
| |||||
13 | Percent of Class Represented by Amount in Row (11)
41.02%* | |||||
14 | Type of Reporting Person
CO |
This Amendment No. 1 amends the Schedule 13D, as previously filed on November 19, 2018 with the Securities and Exchange Commission by Harbin Pharmaceutical Group Co., Ltd, a corporation incorporated in the People’s Republic of China (“Harbin”), by furnishing the information set forth below. Except as otherwise specified in this Amendment No. 1, all previous Items are unchanged.
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated: November 4, 2019
Harbin Pharmaceutical Group Co., Ltd | ||
By: | /s/ Zhenping Zhang | |
Title: | Authorized Signatory |